Sutent set to debut in Korea
Sutent, which was approved by the Korea Food and Drug Administration on July last year, is one of the first in a new class of drugs that selectively targets multiple protein receptors, called receptor...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
